Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bharat Biotech says that its Covaxin demonstrated 100% efficacy against severe COVID-19.

Ocugen Partner Reports Strong Phase 3 Results for Coronavirus Vaccine

This small-cap biotech is currently trailing its rivals in the coronavirus vaccine race. Could a comeback be in the cards?

Could This Little-Known Company's Vaccine Candidate Leapfrog Moderna and Pfizer?

The shares of Ocugen Inc (NASDAQ: OCGN) have received a $10 price target by Roth Capital. These are the details.

OCGN Stock: $10 Target By Roth Capital

The biotech announced positive data for the coronavirus vaccine candidate it hopes to bring to the U.S. market.

Why Ocugen Stock Surged Today

Bionano Genomics

Ocugen Inc. (NASDAQ: OCGN) and Bionano Inc. (NASDAQ: BNGO) are two biopharma stocks moving higher Wednesday. Ocugen is moving after its partner Bharat Biotech announced positive study results, and Bionano gained ground after its system for optical genome mapping was adopted by two large labs in the U.K.'s National Health System.

2 Biopharma Stocks That Look Ready For A Bullish Reversal

Bionano Genomics, Inc. (NASDAQ: BNGO) and Ocugen, Inc. (NASDAQ: OCGN) were among the early movers among biopharma stocks. Bionano Gains On Adoption of Genomic Mapping System By U.K. Labs: Bionano said its Saphyr system for optical genome mapping has been adopted by two large labs belonging to the National Heath System of the U.K.

Why Bionano Genomics, Ocugen Are Rallying Today

OCGN stock is gaining Wednesday morning on news that Bharat Biotech's COVAXIN has an overall 78% efficacy rate. Here's what to know.

OCGN Stock: The Huge COVAXIN News Sending Ocugen Climbing Today

MALVERN, Pa., April 21, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development partner, Bharat Biotech, shared positive results of the second interim analysis of its Phase 3 study of COVAXIN, a whole virion inactivated COVID-19 vaccine candidate. COVAXIN demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 78% with efficacy against severe COVID-19 disease alone of 100%.

Ocugen's COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization

The stock price of Ocugen Inc (NASDAQ: OCGN) increased by over 5% pre-market. This is why it happened.

OCGN Stock: Over 5% Increase Pre-Market Explanation

The U.S. is likely to receive enough vaccines from its current partners, so OCGN stock will probably tumble over the longer term. The post Ocugen's Outlook Is Still Very Bleak appeared first on InvestorPlace.

Ocugen's Outlook Is Still Very Bleak

India's Bharat Biotech has announced COVAXIN capacity expansion to support vaccination campaigns in India and globally amid increased COVID-19 infection cases. MoneyControl says that the capacity expansion has been implemented across multiple facilities in Hyderabad and Bangalore to reach over 700 million doses per year.

Ocugen's Partner Bharat Biotech Ramping Manufacturing To Produce 700M COVID-19 Vaccine Doses Annually

Humanigen

New coronavirus projects make them easy to hype, but they could face strong headwinds soon.

Reddit Traders Can't Get Enough of These 2 Resurgent Biotech Stocks

180 Life Sciences 

Citius Pharmaceuticals

Jaguar Health

Savara

Timber Pharmaceuticals

Zosano Pharma

So, which biotech penny stocks, popular with the Reddit set, offer such opportunity? Consider these seven as ones with potential to live up to online enthusiasm.

7 Reddit Penny Stocks to Buy for a Biotech Boom

Ocugen stock still has a good chance of rising. OCGN stock is worth at least 18% more based on scenario and probability analysis.

Ocugen Stock Still Has a Good Chance of Making Money for Investors

Today, OCGN stock is on the move as the company announced a new Senior VP for the company's manufacturing and supply chain. The post OCGN Stock: The Big News Boosting Support for Ocugen Today appeared first on InvestorPlace.

OCGN Stock: The Big News Boosting Support for Ocugen Today

MALVERN, Pa., April 14, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that John Paul (J.P.) Gabriel will be joining as Senior Vice President (SVP), Manufacturing and Supply Chain.

Ocugen Inc. Announces John Paul Gabriel as Senior Vice President, Manufacturing and Supply Chain

The pullback in OCGN stock could be a rare opportunity as Ocugen stays the course with its suite of potentially life-changing therapies. The post Aggressive Treatment Advancement Makes Ocugen Stock a Solid Pick appeared first on InvestorPlace.

Aggressive Treatment Advancement Makes Ocugen Stock a Solid Pick

Asensus Surgical

Castor Maritime Inc

Genius Brands

Hall of Fame Resort & Entertainment

Ideanomics Inc

Cenntro Electric Group

SNDL Inc.

Zomedica

Once flying high on their status as Reddit stocks, these nine penny stocks are falling back towards prior price levels. The post 9 Reddit Penny Stocks That Are Running Out of Gas appeared first on InvestorPlace.

9 Reddit Penny Stocks That Are Running Out of Gas

OCGN stock bulls should pay close attention to the latest news on the COVAXIN vaccine and on speculative social media chatter. The post OCGN Stock: The Big COVAXIN News That Ocugen Bulls Should Watch appeared first on InvestorPlace.

OCGN Stock: The Big COVAXIN News That Ocugen Bulls Should Watch

GameStop

Marathon Digital Holdings

Riot Blockchain

With gains of 1,259% to 2,801%, these billion-dollar stocks have been unstoppable since early October.

5 Stocks That Made People Millionaires in 6 Months

OCGN stock is not a buy-and-hold investment yet; however, its association with India's Bharat Biotech will continue to drive shares up. The post Ocugen Stock Is an Excellent Day Trade as Long as You Get Out in Time appeared first on InvestorPlace.

Ocugen Stock Is an Excellent Day Trade as Long as You Get Out in Time

The stock price of Ocugen (NASDAQ: OCGN) increased by over 3% pre-market. This is why it happened.

Ocugen Stock Price Increased Over 3% Pre-Market: Why It Happened

The stock price of Ocugen (NASDAQ: OCGN) increased 5.5%. This is why it happened.

Ocugen Stock Price Increased 8.5%: Why It Happened

Amid COVAXIN's approval by Mexican regulators for emergency use, OCGN stock has provided investors with double-digit gains this morning. The post OCGN Stock: One Big Reason Ocugen Is Rocketing Higher Today appeared first on InvestorPlace.

OCGN Stock: One Big Reason Ocugen Is Rocketing Higher Today

Ocugen spent most of March retreating. Now trading perilously close to penny-stock status, OCGN stock is becoming a more interesting bet.

News for Ocugen, Inc. Stock (OCGN)